Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment

Overview

While it is well known that stopping or changing medication with blood thinners in patients who suffer from non-valvular atrial fibrillation (NVAF) increases the risk of ischemic stroke (a condition which occurs when a vessel supplying blood to the brain is obstructed), bleeding or thromboembolism (a condition that happens when a blood clot forms elsewhere in the body and travels through the blood stream to plug another vessel), limited data are available on the number of NVAF patients and the reasons why NVAF patients in Italy stop or change their treatment with blood thinners to prevent stroke or thromboembolism.

By following the NVAF patients in routine clinical practice in Italy who are treated with rivaroxaban to prevent stroke or systemic embolism researchers want to find out how many NVAF patients and for what reasons NVAF patients stopped or changed rivaroxaban treatment. Study data will be collected through patients' routine visits at their treating doctor over a period of 24 months for each patient.

Full Title of Study: “Rivaroxaban Treatment Discontinuation Rates in Routine Clinical Practice in Italy in Patients With Non-valvular Atrial Fibrillation”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 30, 2023

Interventions

  • Drug: Rivaroxaban (Xarelto, BAY59-7939)
    • Treatment dose is following the description of physicians.

Arms, Groups and Cohorts

  • NVAF patients
    • Start treatment with rivaroxaban at the discretion of physician.

Clinical Trial Outcome Measures

Primary Measures

  • Date of start of rivaroxaban treatment
    • Time Frame: 24 months
  • Date of stop of rivaroxaban treatment
    • Time Frame: 24 months
  • Number of patients who discontinue (i.e: number of discontinuation) from study initiation to end of observation/follow up.
    • Time Frame: 24 months

Secondary Measures

  • Reasons for discontinuation of rivaroxaban therapy
    • Time Frame: 24 months
    • therapy discontinuation due to adverse event (AE) therapy discontinuation for non AE related reason physician decision patient lost to follow up, no remote contact patient decision (not related to AE) patient is in stable sinus rhythm patient decided to terminate study participation but agreed to further use of data collected so far. patient decided to terminate study participation and refused further use of collected data. Patient died Treatment switch
  • Reason for dose change of rivaroxaban therapy
    • Time Frame: 24 months
    • Change in Creatinine Clearance (CrCL) Insufficient therapeutic effect Adverse event
  • Reason for switch to other therapy
    • Time Frame: 24 months
    • Ischemic event Bleeding and site of bleeding Adverse drug reaction Drug interaction with other therapies New treatment after switch
  • Treatment adherence: Self-reported medication adherence measured by the MMAS-8 (Morinsky Scale score)
    • Time Frame: 24 months

Participating in This Clinical Trial

Inclusion Criteria

  • Age >= 18
  • Patient with a diagnosis of NVAF
  • New user to rivaroxaban, naïve or non naïve to treatment with oral anticoagulant
  • Patient for whom the decision to initiate treatment with rivaroxaban was made as per physician's routine treatment practice for prevention of stroke and non-central nervous system (CNS) systemic embolism.
  • Signed an informed consent

Exclusion Criteria

  • Patient with heart valve replacement
  • Patient is participating in an investigational program with interventions outside of routine clinical practice

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bayer
  • Collaborator
    • Janssen Research & Development, LLC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Bayer Clinical Trials Contact, (+)1-888-84 22937, clinical-trials-contact@bayer.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.